ArticleBlood research2019

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.

Chur Woo You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.